J&J - Currently Approved Intravenous Formulation of Rybrevant (Amivantamab-Vmjw) Is Not Impacted by Crl
強生 - 目前批准的瑞布韋單抗(Amivantamab-Vmjw)靜脈注射製劑不受Crl的影響
J&J - Currently Approved Intravenous Formulation of Rybrevant (Amivantamab-Vmjw) Is Not Impacted by Crl
強生 - 目前批准的瑞布韋單抗(Amivantamab-Vmjw)靜脈注射製劑不受Crl的影響
使用瀏覽器的分享功能,分享給你的好友吧